Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06596915 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years later Dec 31, 2025 → Dec 31, 2027
See other at-risk trials from Shandong Boan Biotechnology Co., Ltd

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Dec 31, 2025 to Dec 31, 2027
    • Study completion pushed from Dec 30, 2026 to Dec 31, 2027
    • Eligibility criteria expanded, about 11 words
    • Secondary endpoints: details revised at 1 of 8 entries
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a first-in-human (FIH), multicenter, open-label Phase I study to evaluate the safety, tolerability, PK profile, immunogenicity, and preliminary efficacy of BA1302 in patients with advanced solid malignancies. The study includes a dose-escalation phase (Part A) and a dose-expansion phase (Part B).
Trial Details
NCT Number NCT06596915
Lead Sponsor Shandong Boan Biotechnology Co., Ltd
Conditions
(from sponsor)		 Non-Small Cell Lung Cancer, Pancreatic Adenocarcinoma, Breast Cancer, Melanoma
Related terms Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma
Enrollment 167 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov